newsfilter
← Latest News
GlobeNewswire·

Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting

  • Ernexa Therapeutics (NASDAQ: ERNA) announced that preclinical data for its lead candidate ERNA-101 will be presented orally at the 67th ASH Annual Meeting in Orlando, FL.
  • The presentation titled "Gene-modified iPSC-derived MSCs convert immunosuppressive tumor microenvironments (TMEs) into distinct Pro-inflammatory TMEs" will be delivered by Michael Andreeff, MD, PhD.
  • The session is scheduled for December 6, 2025, from 3:00 PM to 3:15 PM EST in the OCCC Chapin Theater (320).
  • The data highlights Ernexa's platform using gene-modified induced pluripotent stem cells (iPSCs) engineered into induced mesenchymal stem cells (iMSCs) to convert immunosuppressive environments into pro-inflammatory ones.
  • ERNA-101 is designed to target ovarian cancer by harnessing iMSCs to release pro-inflammatory cytokines, thereby activating T cells to attack cancer cells.
  • The company's core technology utilizes allogeneic synthetic iMSCs to provide a scalable, off-the-shelf treatment without patient-specific harvesting.
  • Ernexa is also developing ERNA-201, a cell therapy intended to target inflammation for the treatment of autoimmune diseases.
  • The press release includes standard forward-looking statements regarding risks, uncertainties, & potential outcomes of the company's research projects.